Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

4.44
+0.470011.84%
Volume:191.11K
Turnover:814.81K
Market Cap:66.70M
PE:-0.91
High:4.47
Open:3.94
Low:3.94
Close:3.97
Loading ...

Press Release: Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
27 Feb

Jasper Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire
·
26 Feb

Jasper Therapeutics (JSPR) Gets a Buy from UBS

TIPRANKS
·
13 Feb

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

GlobeNewswire
·
10 Feb

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

GlobeNewswire
·
05 Feb

Jasper Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
10 Jan

Jasper Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
09 Jan

Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital

TIPRANKS
·
09 Jan

RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 Jan

Jasper Therapeutics Inc : Btig Cuts Target Price to $64 From $90

THOMSON REUTERS
·
09 Jan

Jasper Therapeutics Inc : RBC Cuts Target Price to $48 From $68

THOMSON REUTERS
·
09 Jan

Promising Efficacy and Safety of Jasper Therapeutics’ Briquilimab Boosts Buy Rating

TIPRANKS
·
09 Jan

Jasper Therapeutics price target lowered to $64 from $90 at BTIG

TIPRANKS
·
09 Jan

Jasper BEACON data ‘net positive,’ says BMO Capital

TIPRANKS
·
09 Jan

Crude Oil Down 1%; US Weekly Jobless Claims Decline

Benzinga
·
09 Jan

BUZZ-Jasper Therapeutics falls about 50% after early-stage data for skin disease drug

Reuters
·
08 Jan

Jasper Therapeutics Shares Fall 50% Premarket After Early-Stage Data From Co's Skin Disease Drug

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Says Preliminary Study Data for Urticaria Treatment Show Reduced Disease Activity

MT Newswires Live
·
08 Jan

BRIEF-Jasper Therapeutics Reports Positive Data From Beacon Study Of Briquilimab In Chronic Spontaneous Urticaria

Reuters
·
08 Jan

Jasper Therapeutics Inc - Data Supports Commencement of Csu Registrational Program Expected to Commence Second Half of 2025

THOMSON REUTERS
·
08 Jan